[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Manavaki, 2006 - Google Patents

Adaptive Correction Schemes for 3-D Positron Emission Tomography Using Non-pure Positron Emitters

Manavaki, 2006

Document ID
14536682551377494517
Author
Manavaki R
Publication year
Publication venue
PQDT-Global

External Links

Snippet

It is widely recognised that scattered radiation is a significant issue in 3-D positron emission tomography (PET). The presence of a scatter background in reconstructed images has been shown to result in contrast losses, the migration of activity from hotter to colder regions and …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
    • G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
    • G01T1/29—Measurement performed on radiation beams, e.g. position or section of the beam; Measurement of spatial distribution of radiation
    • G01T1/2914—Measurement of spatial distribution of radiation
    • G01T1/2985—In depth localisation, e.g. using positron emitters; Tomographic imaging (longitudinal and transverse section imaging; apparatus for radiation diagnosis sequentially in different planes, steroscopic radiation diagnosis)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents

Similar Documents

Publication Publication Date Title
Rösch et al. The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y
Ljungberg et al. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy
Knapp et al. Radiopharmaceuticals for therapy
Chandra et al. Nuclear medicine physics: the basics
Li et al. Quantitative imaging for targeted radionuclide therapy dosimetry-technical review
Khalil et al. Molecular SPECT imaging: an overview
Franc et al. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation
Mikolajczak et al. Radiometals for imaging and theranostics, current production, and future perspectives
Walrand et al. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86 Y or 90 Y imaging?
Wahl et al. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging–guided radiation therapy
Kramer-Marek et al. The role of nuclear medicine in modern therapy of cancer
Benabdallah et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes
Chakraborty et al. Advances in radionuclides and radiolabelled peptides for cancer therapeutics
Rubira et al. 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
Sharma et al. Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
Benfante et al. An overview of in vitro assays of 64Cu-, 68Ga-, 125I-, and 99mTc-labelled radiopharmaceuticals using radiometric counters in the era of radiotheranostics
Park et al. Recent advances in radiopharmaceutical application of matched-pair radiometals
Cuccurullo et al. Small-animal molecular imaging for preclinical cancer research: μPET and μSPECT
Knapp et al. Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine
Koniar et al. In vivo quantitative SPECT imaging of actinium-226: feasibility and proof-of-concept
Kim et al. Preclinical evaluation of a companion diagnostic radiopharmaceutical,[18F] PSMA-1007, in a subcutaneous prostate cancer xenograft mouse model
Piwowarska-Bilska et al. Individualization of radionuclide therapies: challenges and prospects
Williams Anniversary paper: nuclear medicine: fifty years and still counting
Manavaki Adaptive Correction Schemes for 3-D Positron Emission Tomography Using Non-pure Positron Emitters
Gape et al. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review